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ABSTRACT
Oxidative stress plays a key role in the pathogenesis of cancer and many metabolic diseases; therefore, an effective antioxidant therapy 
would be of great importance in these circumstances. Nevertheless, convincing randomized clinical trials revealed that antioxidant 
supplementations were not associated with significant reduction in incidence of cancer, chronic diseases and all-cause mortality. As 
oxidation of essential molecules continues, it turns to nitro-oxidative stress because of the involvement of nitric oxide in pathogenesis 
processes. Peroxynitrite damages via several distinctive mechanisms; first, it has direct toxic effects on all biomolecules and causes 
lipid peroxidation, protein oxidation and DNA damage. The second mechanism involves the induction of several transcription factors 
leading to cytokine-induced chronic inflammation. Finally, it causes epigenetic perturbations that exaggerate nuclear factor kappa-
B mediated inflammatory gene expression. Lessons-learned from the treatment of several chronic disorders including pulmonary 
diseases suggest that, chronic inflammation and glucocorticoid resistance are regulated by prolonged peroxynitrite production. 
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for the accumulation of age-related cellular debris, and 
that this damage is an important contributor not only 
for aging but also for chronic diseases (de Grey, 2006). 
In theory, antioxidant interventions should modify 
the biochemical and molecular events causing cancer and 
chronic diseases, correct physiological changes responsible 
for symptoms and signs of several cancers, and decrease 
the susceptibility to chronic diseases and cancer. Therefore, 
in excess of 70% of the American population uses dietary 
supplements daily, of which antioxidant vitamin and min-
eral supplements are the most common (Woo, 2007). The 
idea that the pathophysiologic processes caused exclusively 
by oxygen-derived free radicals could presumably be allevi-
ated by conventional antioxidants such as vitamin E or C 
and/or intracellular enzymatic antioxidants seems worthy. 
Nevertheless, several studies found that the antioxidants 
had little effect in terms of preventing several cancers and 
chronic diseases. 
Introduction
The free radical theory of aging has gained acceptance and 
has matured in the past 50 years since it was proposed by 
Harman in 1956 (Harman, 2003; 2006). Since not only free 
radicals lead to damage of biomolecules but also other cel-
lular reactive by-products of normal metabolism, the theory 
has been extended to the ‘oxidative damage theory’ which 
suggests that reactive oxygen species (ROS) are responsible 
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In the Physicians’ Health Study, data from 83,639 US 
male physicians, of whom 29% were taking either vitamin E, 
vitamin C, or multivitamin supplements on a self-selected 
basis, was evaluated (Muntwyler et al., 2002). The authors 
concluded that these supplements were not associated with 
a significant reduction in total cardiovascular diseases or 
coronary heart disease mortality. Another prospective 
study reported that vitamins E and C and certain carot-
enoids did not reduce the risk of stroke in 43,738 men 40 
to 75 years old with no cardiovascular disease or diabetes 
(Ascherio et al., 1999). The Heart Outcome Prevention 
Evaluation (HOPE) trial (Lonn et al., 2002), a randomized 
controlled trial in patients 55 years or older who had car-
diovascular disease or diabetes, revealed that taking 400 
IU vitamin E daily for an average of 4.5 years was without 
influence on cardiovascular outcomes or nephropathy. A 
randomized, double-blind, placebo-controlled trial with 
vitamin E interestingly resulted in increased blood pressure 
in type 2 diabetic patients (Ward et al., 2007). The authors 
concluded that the mechanism for this increase remains 
unknown; however, it appears to be independent of changes 
in oxidative stress. Additionally, a meta-analysis of a large 
body of published data revealed that antioxidant vitamins 
do not significantly reduce risk of cardiovascular death 
(Vivekananthan et al., 2003). 
The lung is the only organ in the entire human archi-
tecture, which has the highest exposure to atmospheric 
oxygen. Owing to its large surface area and blood supply, 
the lung is susceptible to oxidative injury by virtue of myri-
ads of reactive forms of oxygen species and free radicals. 
Exogenous oxidants and increased oxygen burden in lung 
due to accumulation of inflammatory cells in the lower 
respiratory tract, including macrophages and neutrophils 
are generally accepted as initial step in patients with acute 
respiratory distress syndrome, idiopathic pulmonary fibro-
sis and chronic obstructive pulmonary disease (COPD)
(Rahman and MacNee, 1996; Wallaert et al., 1990). Free 
radical reactions have been suggested to play a contributory 
role in the fibrogenesis either directly or through inflamma-
tory responses (Poli and Parola, 1997). Tissue injury almost 
invariably leads to oxidative stress. In theory, antioxidant 
interventions should modify the biochemical and molecu-
lar events causing COPD correct physiological changes 
responsible for symptoms and signs of COPD and reduce 
the susceptibility to complications associated with COPD 
(Kirkham and Rahman, 2006). 
Vitamin A, C and E, β-carotene, N-acetylcysteine (NAC) 
and its derivative erdosteine are the most frequently used 
antioxidants. Among them NAC, which was introduced as 
a mucolytic agent for COPD more than 50 years ago, is a 
well-known antioxidant and has been extensively studied 
in both experimental and clinical studies. In experimental 
studies, NAC and erdosteine, generally reduce lung injury in 
many animal models of diseases (Aitio, 2006; Moretti and 
Marchioni, 2007).
Several randomized-controlled studies have shown 
that 600 mg NAC given daily reduce exacerbations of 
COPD (Boman et al., 1983; Pela et al., 1999; Rasmussen 
and Glennow, 1988). Most investigations of the role of 
antioxidant substances in COPD, however, have been incon-
clusive because they were short-term and only assessed 
immediate effects (Riccioni et al., 2007). Moreover, in 
acute exacerbations of COPD, addition of NAC to standard 
treatment did not modify the outcome (Black et al., 2004). 
A recent extensive multi-centre study (BRONCUS), where 
the patients were followed for 3 years, reported that at least 
the dose of NAC 600 mg daily is ineffective at prevention of 
deterioration in lung function and prevention of exacerba-
tions in patients with COPD (Decramer et al., 2005). 
Bjelakovic et al. (Bjelakovic et al., 2004) examined a 
series of studies (170,525 participants) and found that 
neither antioxidant vitamins singly (e.g., vitamin E and β 
carotene) nor several combinations (e.g., β carotene, vitamin 
C and E) showed effect on the incidence of gastrointesti-
nal cancer. Lawson et al. (Lawson et al., 2007) conducted 
a prospective observational study and investigated the 
association between multivitamin use and prostate cancer 
risk in 295,344 men enrolled in the National Institutes of 
Health (NIH) – AARP Diet and Health Study. The authors 
found that use of multivitamins more than seven times per 
week, when compared with never use, was associated with 
a doubling in the risk of fatal prostate cancer. A recent pro-
spective cohort of 77,721 men and women aged 50–76 years 
declared that supplemental multivitamins, vitamin C and 
E were not associated with a decreased risk of lung cancer. 
Moreover, supplemental vitamin E was associated with a 
small increased risk (Slatore et al., 2008).
The results are in accord with the results of systematic 
reviews and meta-analyses of randomized clinical trials 
examining the efficacy of antioxidant supplements on all-
cause mortality. A meta-analysis found that in 11 trials, 
high doses of vitamin E resulted in slightly but significantly 
higher rate of all-cause mortality when compared with 
placebo (Miller et al., 2005). Another systematic review 
and meta-analysis that included 68 randomized trials with 
232,606 participants (385 publications) also showed that 
antioxidant vitamins may increase all-cause mortality 
(Bjelakovic et al., 2007). 
Why antioxidant vitamins do not 
prevent chronic diseases?
A possible explanation for the potential negative effect of 
antioxidant supplements might be that ROS in moderate 
concentrations are essential mediators of reactions by which 
the body gets rid of unwanted cells. Thus, if administration 
of antioxidant supplements decreases free radicals, it may 
interfere with essential defensive mechanisms for ridding 
the organism of damaged cells, including those that are 
injured, precancerous and cancerous (Linnane et al., 2007). 
Moreover, antioxidants are potential electron donors and 
they exhibit both reduced and oxidized forms. Once they 
donate an electron to neutralize a free radical, they are 
transformed from a reduced to an oxidized state. Usually, 
the oxidized form will be regenerated to the reduced 
state through the mechanism known as redox reaction or 
recycling. Since these antioxidants are electron donors and 221
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exhibit redox reactions, their oxidized forms also can oxi-
dize other molecules, thus, classical antioxidants are often 
reported to be pro-oxidants (Beckman and Koppenol, 1996; 
Bjelakovic et al., 2007; Pacher et al., 2007). 
Another possible explanation might be that the stud-
ies were conducted in middle- and high income countries 
among populations already well saturated with vitamins. 
The American diet provides 120% of the recommended 
dietary allowances for antioxidant vitamins and dietary 
vitamin E deficiency has never been reported in the United 
States (Herbert, 1994). Our diets typically contain safe 
levels of vitamins, but high-level antioxidant supplements 
could potentially upset an important physiologic balance 
(Salganik, 2001). Nevertheless, there is no doubt that oxi-
dative stress is often an early and key event that activates 
numerous pathways involved in several cancer and develop-
ment of chronic diseases including type II diabetes, hyper-
tension, atherosclerosis and inflammatory lung diseases. 
On the basis of published literature, a novel molecular 
approach to resolve the apparent controversy and to protect 
cells from oxidative stress is warranted (Ceriello, 2006). 
Nitro-oxidative stress: an explanation for the controversy
A theoretical explanation for the failure of antioxidant vita-
mins to protect against disease relates to the fact that with 
the discovery of nitric oxide (NO) and nitric oxide synthase 
(NOS) family, oxidative stress became more complex then 
previously realized. A vital, ubiquitous molecule, NO, 
has numerous roles in regulating physiological processes. 
Because of affinity of NO for the superoxide anion radical 
(O2
•−), neither enzymatic nor pharmacologic levels of con-
ventional antioxidants successively compete with NO for 
O2
•−; as a result, high peroxynitrite (ONOO−) levels follow 
(Beckman and Koppenol, 1996). Therefore, the oxidative 
stress theory has expanded into new areas, particularly 
after the involvement of ONOO− as a causative reactant 
(Pacher et al., 2007).
It is presumed that initially ROS production reduced 
the endothelial NOS (eNOS)-derived NO within endo-
thelial cells while activating inducible NOS (iNOS) which 
causes almost a 1,000-fold higher NO production than 
eNOS does under physiologic circumstances. iNOS is 
predominantly expressed in inflammatory cells such as 
macrophages, although epithelial cells from affected tissues 
also express the enzyme. Intensified expression of iNOS 
has been detected in virtually all cell types tested includ-
ing macrophages, fibroblasts, chondrocytes, osteoclasts, 
and epithelial cells and results in the production of large 
amounts of NO in animals and patients with inflammatory 
diseases (Cooke and Davidge, 2002; Moncada et al., 1991; 
Stockklauser-Farber et al., 2000; Weidig et al., 2004). The 
level of iNOS expression is well correlated with the degree 
of inflammation. A controversy arises from observations 
reporting both cytotoxic and cytoprotective effects of NO. 
In cases where NO was found cytotoxic, it was questioned 
whether NO, directly or indirectly, or through the forma-
tion of more reactive species such as the ONOO− exerted 
these effects. Thus, it is believed that oxygen-based free 
radicals are only an initial step in the pathophysiologic 
mechanisms of aging and chronic diseases (Dedon and 
Tannenbaum, 2004). The combination of elevated NO plus 
excess O2
•− with the formation of high levels of ONOO− is 
the proverbial intracellular “devil’s triangle” (Figure 1). 
The “devil’s triangle” changes the nature of oxidative stress
In the last two decades, NO was found, when produced in 
excess, to be a toxic molecule which damages and even kills 
cells. In the presence of excess O2
•− and abundant NO, this 
latter vital molecule shows its dark side. Neither O2
•− nor 
NO is particularly toxic by themselves because there are 
efficient means to minimize their accumulation (Beckman 
and Koppenol, 1996). Thus, O2
•− is rapidly removed by the 
superoxide dismutases (SOD) with the isoenzymes of this 
molecule being located in the mitochondria (Mn-SOD), 
cytosol (Cu/Zn-SOD), and extracellular (EC-SOD) com-
partments. Physiologically, NO is removed by its rapid 
diffusion through tissues into red blood cells (Joshi et 
al., 2002), where it is quickly converted to nitrate by a 
reaction with oxyhemoglobin. This limits the biological 
half-life of NO in vivo to less than a second. However, when 
both O2
•− and NO are generated within a few molecular 
diameters of each other, they combine spontaneously to 
form ONOO− in a diffusion-limited reaction. Basically, 
every time NO and O2
•− collide, they form ONOO−. NO 
is the only known biological molecule that reacts faster 
with O2
•− and is produced in such high concentrations 
that it out-competes endogenous SOD; hence, the creation 
of the “devil’s triangle” (Figure 1). Consequently, from a 
biological viewpoint, the reaction of O2
•− with NO to form 
ONOO− is inevitable. Any of several antioxidants may have 
beneficial effects in these acute situations (e.g., acute lung 
injury, ischemia-reperfusion, myocardial infarction, exog-
enous inflammatory agent-induced acute inflammation). 
However, in case of chronic oxidative stress, once iNOS is 
totally activated, ordinary antioxidants provide little pro-
tection due to massive ONOO− generation. Thus, in case 
of chronic oxidative stress such as chronic hyperglycemia, 
dyslipidemia, tobacco smoking, exposure to allergens, 
prolonged drug use which are known to produce oxidative 
damage, conventional antioxidants become ineffective 
(Korkmaz et al., 2008b). 
Consequences of peroxynitrite production
Once ONOO− forms, it can act via several distinct 
mechanisms; first it has direct toxic effects leading to 
lipid peroxidation, protein oxidation and DNA damage. 
The second mechanism involves the induction of several 
transcription factors including nuclear factor-kappa B 
(NF-κB) and activator protein-1 (AP-1) leading to cytokine-
induced chronic inflammation (Figure 1). This cascade, 
once activated, causes the release of pro-inflammatory 
cytokines including tumor necrosis factor-α (TNF-α) and 
interleukin-1β (IL-1β), and a variety of chemokines which 
induces widespread inflammation. During this process, 
several adhesion molecules and monocyte chemoattractant 
proteins also become involve widening the inflammatory 222
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response and vascular events (Forstermann and Munzel, 
2006; Pacher et al., 2007). 
A direct toxic effect of ONOO− at the site of its produc-
tion involves an intriguing process which decides the fate of 
cells. ONOO− is per se not a radical but is a powerful nitro-
sating agent. ONOO− interacts with and covalently modifies 
all major types of biomolecules including membrane lipids, 
thiols, proteins and DNA (Demicheli et al., 2007; Pacher et 
al., 2007). In addition, ONOO− can yield the hydroxyl (OH•) 
and nitrogen dioxide (NO2
•) radicals (less than 30% yield). 
Although this is a minor process in biology, OH• is a potent 
reactant and oxidizes relevant targets including amino 
acids (tyrosine, phenylalanine, histidine), carbohydrates 
and lipids (Alvarez and Radi, 2001; 2003). The generation of 
ONOO− also decreases the availability of NO for G-protein 
stimulation and vasodilatation, thus further contributing 
to endothelial dysfunction leading to elevated blood pres-
sure. In addition, ONOO− can inhibit SOD as well as other 
antioxidant molecules and systems, which leads to positive 
feedback cycles of intracellular oxidant generation and 
increased radical damage (Szabo, 2003). ONOO− activates 
matrix metalloproteinases (MMPs) (Okamoto et al., 2001; 
Wu et al., 2001) and triggers the expression of selectins and 
cellular adhesion molecules via enhancement of NF-κB 
activation thereby promoting pro-inflammatory responses. 
The mutagenic properties of ONOO−-induced modified 
products have also been determined (Juedes and Wogan, 
1996; Whang et al., 1998). Several studies have shown that 
NO itself does not induce DNA single-strand breaks in vitro 
in plasmid DNA (Masuda et al., 2002; Tamir et al., 1996), 
whereas exposure of plasmid DNA to pre-formed ONOO− 
(Yoshie and Ohshima, 1997) or NO plus O2
•− generated 
concurrently induces such strand breaks (Chaturvedi et 
al., 1998). Single strand breakage can be induced by treat-
ment with very low concentrations of ONOO− indicating 
that this agent is a potent inducer of this type of damage 
to DNA (Yermilov et al., 1996). DNA cleavage caused by 
ONOO− was observed at almost every nucleotide, with a 
small preference for guanine residues. Furthermore, it has 
been reported that ONOO− inactivates several enzymes 
that are critically involved in the repair of DNA damage. 
These observations suggest additional pathways by which 
ONOO− may be associated with not only elevated DNA 
damage but also impairment of DNA repair capacity (Chien 
et al., 2004). 
A crucial step: poly(ADP ribose) polymerase activation 
ONOO− induces both apoptosis and necrosis of cells. 
More highly elevated exposure of this agent is associated 
wi th  n e c r o s is  as  o p p o s e d  t o  a p o p t o s is  ( Levran d  et al., 
2006; Szabo, 2003; Virag et al., 2003). In this mechanism, 
activation of the DNA repair enzyme poly(ADP ribose )
polymerase-1 (PARP-1), a member of PARP enzyme family, 
mediates ONOO−-induced necrosis. PARP-1 detects and 
signals DNA strand breaks induced by a variety of geno-
toxic insults including ionizing radiation, alkylating agents, 
oxidants (essentially OH•, ONOO−), and free radicals 
(Korkmaz et al., 2005; Korkmaz et al., 2007; Korkmaz et 
al., 2006; Szabo, 2006; Yaren et al., 2007). Upon binding to 
DNA, strand breaks occur and PARP transfers ADP-ribose 
units from the respiratory coenzyme nicotinamide adenine 
dinucleotide (NAD+) to various nuclear proteins. From a 
physiological view point, PARP-1 activity and poly(ADP-
ribosyl)ation reactions are implicated in DNA repair pro-
cesses, the maintenance of genomic stability, the regulation 
of gene transcription, and DNA replication. An important 
function of PARP-1 is to allow DNA repair and cell recovery 
under conditions associated with a low level of DNA dam-
age. In case of severe DNA injury, overactivation of PARP-1 
depletes the cellular stores of NAD+, an essential cofactor 
in principal energy production mechanisms including the 
glycolytic pathway, the tricarboxylic acid cycle, and the 
mitochondrial electron transport chain. As a result, the loss 
of NAD+ leads to a marked reduction in the cellular pools 
of ATP, resulting in cellular dysfunction and death via the 
necrotic pathway (Szabo, 2003; Virag et al., 2003). This is 
known as the “suicide hypothesis” of PARP activation and 
seems to be a regulatory mechanism to eliminate cells after 
irreversible DNA injury. A vast amount of experimental 
evidence has established that the PARP-1 pathway of cell 
death plays a pivotal role in tissue injury and organ dysfunc-
tion in numerous disease processes (de la Lastra et al., 2007; 
Korkmaz et al., 2006; 2008a).
A novel mechanism of peroxynitrite-induced toxicity; 
lessons-learned from treatment of patients with 
chronic obstructive pulmonary disease (COPD)
One of the major problems in the treatment of COPD is 
glucocorticoid resistance. Although inhaled glucocorticoids 
are highly effective in asthma, they provide relatively little 
therapeutic benefit in COPD, despite the fact that active 
airway and lung inflammation is present. This may reflect 
that the inflammation in COPD is not suppressed by gluco-
corticoids, with no reduction in inflammatory cells, cyto-
kines or proteases in induced sputum even with high doses 
of inhaled and oral glucocorticoids (Loppow et al., 2001). 
Furthermore, histological analysis of peripheral airways of 
patients with severe COPD shows an intense inflammatory 
response, despite treatment with high doses of inhaled 
glucocorticoids (Hogg et al., 2004). There is increasing evi-
dence for an active steroid resistance mechanism in COPD, 
as glucocorticoids fail to inhibit cytokines (e.g., IL-8 and 
TNF-α) that they normally suppress (Culpitt et al., 1999). 
The predominant effect of glucocorticoids is to switch 
off multiple inflammatory genes (encoding cytokines, che-
mokines, adhesion molecules and inflammatory enzymes) 
that have been activated during the chronic inflamma-
tory process. The increased expression of most of these 
inflammatory proteins is regulated at the level of gene 
transcription through the activation of pro-inflammatory 
transcription factors, such as nuclear NF-κB and AP-1. The 
molecular pathways involved in regulating inflammatory 
gene expression are now being delineated and it is now 
clear that chromatin remodeling and a variety of epigenetic 
mechanisms play a critical role in the transcriptional control 
of genes. Stimuli that switch on inflammatory genes do so 
by changing the chromatin structure of the inflammatory 
gene, whereas glucocorticoids reverse this process. 223
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Recent evidence suggests that ONOO−-induced histone 
modifications may play a role in the mechanism of gluco-
corticoid resistance (Barnes et al., 2004; Ito et al., 2004; 
Mroz et al., 2007) . Therefore, ONOO − complicates the 
pathophysiology and treatment of COPD via several man-
ners; it causes severe nitro-oxidative stress and harms all 
biomolecules including lipids, proteins, DNA and activates 
PARP-1 (Hageman et al., 2003). It exaggerates inflammation 
via enhancing NF-  B pathway and it directly causes gluco-
corticoid resistance by blocking glucocorticoid-dependent 
inflammatory gene silencing (Barnes et al., 2004; Mroz et 
al., 2007). 
A summary of epigenetic regulation 
of gene expression
The term epigenetic describes the study of inheritable 
alterations in gene expression that occur in the absence of 
changes in genome sequence. This is in contrast to genetics, 
Figure 1. Basic mechanism of peroxynitrite-induced toxicity and related pathways (Korkmaz, 2008b).
Oxidative stress is often an early and key event that activates numerous pathways involved in several cancer and development of chronic diseases. 
If the causative agent (e.g., hyperglycemia, cigarette smoking, UV lights, and chemical toxicants) persists, eventually iNOS is activated and ONOO– is 
formed. By then, cellular stress is transformed from oxidative only to nitro-oxidative. ONOO– exerts its harmful eff  ects directly and indirectly. It causes 
activation of transcriptional factors leading to pro-infl  ammatory gene expression. During this process, nitro-oxidative stress also involves an infl  am-
matory response. Interactions between transcriptional factors and pro-infl  ammatory products lead to a vicious cycle of damage. The cytokines 
spread the infl  ammatory signals through the circulation. Unless excess O2•– and iNOS-derived NO production are terminated, this mechanism 
continues to propagate damage within cell. Moreover ONOO– directly damage all macromolecules including lipids, proteins and DNA. ONOO–-
induced DNA damage is sensed by DNA repair enzymes, in particular poly(ADP ribose) polymerase (PARP). In presence of severe genomic damage, 
overactivation of PARP causes cellular NAD+ and ATP depletion by attempting a repair process. This drives cells into an energy crisis eventually leading 
to necrosis. This futile mechanism, so-called “suicide hypothesis” of PARP activation, is reportedly involved in many diseases related to nitro-oxidative 
stress. Since the mitochondrion has its own DNA and PARP enzyme, this pathophysiologic process also takes place within the mitochondrion. It is 
well known that, both oxygen and nitrogen-based radicals are prone to directly damage this organelle. Consumption of the majority of NAD+ by 
PARP also slows the rate of glycolysis and mitochondrial respiration, and eventually leads to cellular dysfunction and death.224
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which deals with the transmission of information based on 
differences in DNA sequence. Therefore, epigenetic gene 
regulation requires molecular mechanisms that encode 
information in addition to the DNA base sequence and can 
be propagated through mitosis and meiosis. Our current 
understanding of epigenetic regulation of gene expression 
involves basically two classes of molecular mechanisms: 
histone modifications and DNA methylation. A variety 
of enzymes are involved in this process including most 
importantly histone deacetylases (HDACs), histone acetyl 
transferases (HATs) and DNA methyltransferases (DNMTs) 
(Miremadi  et al. ,  2 00 7 ) .  Al t e r a ti o n  o f  th e  s tru ctur e  o f  
chromatin is critical to the regulation of gene expression. 
Chromatin is made up of nucleosomes, which are particles 
consisting of DNA associated with an octamer of two 
molecules each of the core histone proteins (H2A, H2B, H3 
and H4), around which 146 base pairs of DNA are wound. 
In resting conditions, DNA is wound tightly around these 
basic core histones, excluding the binding of the enzyme 
RNA polymerase II, which activates the formation of mes-
senger RNA. This conformation of the chromatin structure 
is described as closed, and is associated with the suppression 
of gene expression. 
DNA methylation is another regulation, in which a 
cytosine base is modified by a DNMT at the C5 position of 
cytosine, a reaction that is carried out by various members 
of a single family of enzymes. CpG islands are CG-rich 
sequences located near coding sequences and serve as 
promoters for the associated genes and methylation of 
CpG sites is maintained by DNMTs. DNA methylation is 
commonly associated with gene silencing and contributes 
to transcriptional regulation of tissue-specific genes during 
cellular differentiation. The methylation status of CpG 
islands within promoter sequences works as an essential 
regulatory element by modifying the binding affinity of 
transcription factors to DNA binding sites. Gene transcrip-
tion only occurs when the chromatin structure is opened 
up, with unwinding and properly methylated of DNA so that 
Figure 2. Lessons-learned from treatment of patients with COPD and proposed overall mechanism of ONOO–-induced cell toxicity. 
NF-κB and AP-1 switch on infl  ammatory genes by inducing several co-activators (e.g., p300/CBP) that have intrinsic HAT activity. Gene transcription 
only occurs when the chromatin structure is opened up, with unwinding and properly methylated of DNA so that RNA polymerase II and basal 
transcription complexes can now bind to the naked DNA to initiate transcription. Glucocorticoids switch off   multiple infl  ammatory genes that 
have been activated by NF-κB and AP-1 during the chronic infl  ammatory process. Both activation of HDAC and inhibition of HAT may be involved 
in glucocorticoid-dependent gene silencing. As found in patients with COPD, ONOO– may block the HDAC activity, thereby cause glucocorticoid 
resistance. This mechanism may partly explain the controversy that antioxidants that only have the capability of scavenging superoxide, but not 
peroxynitrite may fail in a variety of chronic oxidative stress. 225
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RNA polymerase II and basal transcription complexes can 
now bind to the naked DNA to initiate transcription. 
The epigenotype can be transmitted from a parent cell 
to a daughter cell maintaining a specific epigenotype within 
cell lineages. Thus, the phenotype is a result of the genotype, 
the specific DNA sequence, and the epigenotype. The geno-
type must exist in a particular chromatin configuration, the 
epigenotype, which allows a secondary level of fine control 
over gene expression. The epigenotype shows far greater 
plasticity than the genotype, and it has been speculated 
that epigenetic errors could be a major contributor to 
human diseases (Jiang et al., 2004). Epigenotype is gener-
ally accepted as being less stable than the genetic system, 
and more sensitive to environmental (McLachlan, 2001), 
nutritional (Gallou-Kabani and Junien, 2005) and chemical 
toxicants (Bombail et al., 2004; McLachlan et al., 2001). 
Peroxynitrite-dependent glucocorticoid resistance in the 
treatment of chronic obstructive pulmonary diseases
Glucocorticoids produce their effect on responsive cells 
by activating the glucocorticoid receptor (GR) to directly 
or indirectly regulate the transcription of target genes. 
The number of genes per cell directly regulated by glu-
cocorticoids is estimated to be between 10 and 100, but 
many genes are indirectly regulated through an interac-
tion with other transcription factors and co-activators. 
Most of the anti-inflammatory actions of glucocorticoids 
are due to suppression of the actions of AP-1 and NF-κB 
(Barnes, 2006). The activated GR may directly bind to p300/
CBP or other co-activators to inhibit their HAT activity, 
thus preventing the subsequent histone acetylation and 
chromatin remodeling and leads to inhibition of AP-1 and 
NF-κB-induced pro-inflammatory gene expression such as 
TNF-α, IL-1β and adhesion molecules (Adcock et al., 2004). 
Another mechanism is to reverse this process by deacetylat-
ing the hyper-acetylated histones through the recruitment 
of HDAC-2 to the activated co-activator complex (Ito et al., 
2006). This process results in rewinding and compaction 
of DNA, exclusion of RNA polymerase, and suppression of 
inflammatory gene transcription. This mechanism could 
account for the anti-inflammatory effect of glucocorticoids 
in inflammatory diseases (Adcock et al., 2004; Figure 2). 
Patients with COPD has been shown to have a progres-
sive reduction in total HDAC activity that reflects the 
severity of the disease (Ito et al., 2005; 2006). There is also 
a reduction in total HDAC activity in peripheral lung, bron-
chial biopsy specimens, and alveolar macrophages from 
COPD patients, and this is correlated with disease sever-
ity and with increased gene expression of IL-8 (Ito et al., 
2005). HDAC activity is reduced in alveolar macrophages of 
cigarette smokers compared to nonsmokers, and this is cor-
related with increased expression of inflammatory genes in 
these cells (Ito et al., 2001). Importantly, HDAC-2 has been 
found to mediate the deacetylation of the GR that enables 
NF-κB suppression (Ito et al., 2006). It was suggested that 
HDAC-2 is a key enzyme involved in the suppression of 
NF-κB-mediated inflammatory gene expression. Therefore, 
HDAC-2 reduction is involved in both glucocorticoid resis-
tance and NF-κB-mediated inflammatory gene expression. 
The importance of this mechanism in glucocorticoid-
insensitive COPD disease is emphasized by over-expression 
of HDAC-2, which restores glucocorticoid sensitivity in 
primary cells from these patients.
The reasons for the reduction in HDAC, particularly 
HDAC-2, in COPD are not yet completely understood. 
However, there is increasing evidence that this may be due 
to inactivation of the enzyme of nitro-oxidative stress, in 
particular ONOO− (Marwick et al., 2004; Moodie et al., 
2004; Rahman et al., 2004). As mentioned previously, NF-κB 
is a transcription factor implicated in the transcriptional 
upregulation of inflammatory genes in response to changes 
in cellular oxidation-reduction status. Target genes of NF-  B 
in various cell types encode proteins involved in immune, 
inflammatory and acute-phase responses. Recently, con-
siderable progress has been made in understanding the 
details of the signaling pathways that regulate NF-  B activ-
ity, particularly those responding to the pro-inflammatory 
cytokines TNF-α and IL-1 (Wang et al., 2002).
Once in the nucleus, NF-κB undergoes post-translational 
modifications (e.g., phosphorylation) that increase NF-κB 
transcriptional activation. These modifications facilitate 
complexes with co-regulators such as p300/CBP that 
promote NF-κB transcriptional responses (Perkins et al., 
1997). For example, phosphorylated p65 is more effective 
at displacing transcriptionally repressive HDAC complexes 
such as p50-HDAC from κB enhancers within target genes. 
p300 has been implicated in this acetylation but other 
HATs could also be involved (Chen and Greene, 2003). 
Furthermore, HDACs such as HDAC-3 can deacetylate p65. 
The balance between HATs and HDACs could influence the 
transcriptional potential of NF-κB. Other transcription fac-
tors are also post-transcriptionally modified. For example 
p53 can be phosphorylated and acetylated affecting its 
transcriptional responses (Roy et al., 2005). These post-
translational modifications could provide a transcriptional 
“histone code” allowing gene transcription to be targeted to 
specific genes. 
To allow NF-κB as well as the transcriptional machinery 
access to target genes, chromatin remodeling is required. 
The acetylation of histone tails surrounding the promoters 
for NF-κB target genes has been shown. Acetylation of his-
tone tails is regulated by HATs and HDACs similar to NF-  B 
acetylation. Indeed, many NF-κB targeted genes have p300/
CBP complexes on their promoters thereby increasing his-
tone acetylation (Chen and Greene, 2003). Moreover, HDAC 
inhibitors that increase acetylation of proteins require an 
intact NF-κB signaling pathway to induce cell cycle arrest in 
human myeloid leukemia cells (Dai et al., 2003). Conversely, 
deacetylation of histones impairs and blocks NF-κB action 
(Campbell et al., 2004). 
One confusing problem in NF-κB transcriptional regula-
tion is the contradictory functions of NF-κB in apoptosis 
and cell survival. Many stimuli give survival responses 
to cells that are also mediated by NF-κB. For example, 
an early cellular response to oxidative stress is an activa-
tion of antioxidant enzymes, including SOD, glutathione 
peroxidase (GSH-Px) and catalase (CAT). Likewise, the 
antioxidant enzyme genes are present in the promoter gene 226
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region of κB response elements (Sun and Oberley, 1996). Xu 
et al. described that NF-κB is critical for TNF-α and IL-1β 
induced Mn-SOD expression (Xu et al., 1999). Kiningham 
et al. reported that the induction of Mn-SOD by phorbol 
12-myristate 13-acetate (PMA), a well-known inflammatory 
agent, and cytokines depend on the increased NF-κB activ-
ity. They found that simultaneous treatment with PMA, 
TNF-α and IL-1β synergistically increases Mn-SOD induc-
tion through the NF-κB pathway (Kiningham et al., 2001). 
Song et al. (2005) reported that oxidative stress increases 
NF-κB DNA binding activity in an experimental ischemia-
reperfusion model. They further revealed that increased 
expression of SOD and subsequent decrease of oxidative 
stress promoted the neuroprotective expression profile of 
NF-κB-related genes resulting in neuroprotection (Song et 
al., 2007). Supportingly, Mattson et al. (2000) reported that 
the NF-κB subunit plays a role in regulating neuronal sur-
vival in neurodegenerative diseases, probably by targeting 
genes such as Mn-SOD.
On the other hand, iNOS and cyclooxygenase-2 (COX-2) 
are also regulated by NF-κB and lead to excess prostaglan-
din (PG) synthesis. It is known that NF-κB represents one 
of the most relevant signaling pathways that mediates the 
expression of iNOS following many extracellular mediators, 
including endotoxin and inflammatory cytokines (Mollace 
et al., 2005). How the same transcription factor, NF-κB, 
can regulate several genes with juxtaposed and/or opposed 
functions? NF-κB may have diverse effects over gene expres-
sion and may have several faces as recently reviewed by 
Graham and Gibson (Graham and Gibson, 2005). The pos-
sible reason of this that subunits of NF-κB and/or different 
combinations of activated subunits may cause a variety of 
epigenetic actions upon the histone code of targeted genes 
and lead diverse variety of gene expression. Recently, Song 
et al. (2007) reported that reduced oxidative stress promotes 
NF-κB-mediated neuroprotective gene expression and alle-
viates oxidative stress after transient focal cerebral ischemia.
Concluding remarks
Since antioxidant supplements can reduce the oxidative 
stress, they may help in acute oxidative stress. In case 
of chronic circumstances (e.g., chronic hyperglycemia, 
tobacco smoking, exposure to chemical and dietary toxins), 
oxidative stress turns nitro-oxidative stress and antioxidant 
supplements can no longer reduce oxidative stress and 
redox status of cells are perturbed. There is no doubt that, 
nitro-oxidative stress plays a crucial role in virtually all 
acute and chronic inflammatory circumstances irrespec-
tive to causative agents and promotes NF-κB-mediated 
inflammatory gene expression by both inducing NF-κB 
itself and reducing HDAC levels of inflammatory genes. 
Therefore, a possible beneficial drug should exert not 
only antioxidant efficacy but also iNOS inhibitory and/or 
ONOO− scavenging properties. This kind of therapeutics 
may help the patients with chronic inflammatory diseases 
as an add-on treatment along with steroid or non-steroid 
anti-inflammatory drugs. 
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